Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $90.00 at HC Wainwright

Vera Therapeutics (NASDAQ:VERA) had its price objective raised by equities research analysts at HC Wainwright from $85.00 to $90.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 272.05% from the company’s current price.

A number of other research firms have also weighed in on VERA. Cantor Fitzgerald reissued an “overweight” rating on shares of Vera Therapeutics in a report on Thursday, September 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, October 8th. JPMorgan Chase & Co. decreased their price target on Vera Therapeutics from $53.00 to $52.00 and set an “overweight” rating on the stock in a research report on Friday. Wolfe Research reissued a “peer perform” rating on shares of Vera Therapeutics in a research note on Monday, August 4th. Finally, Bank of America started coverage on Vera Therapeutics in a research note on Thursday, October 16th. They set a “buy” rating and a $48.00 target price for the company. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.90.

Vera Therapeutics Trading Down 4.1%

Shares of NASDAQ:VERA opened at $24.19 on Monday. Vera Therapeutics has a one year low of $18.53 and a one year high of $51.61. The stock has a market capitalization of $1.54 billion, a PE ratio of -6.06 and a beta of 1.22. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21. The company’s 50-day moving average price is $27.33 and its two-hundred day moving average price is $24.15.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same quarter in the previous year, the business earned ($0.85) earnings per share. On average, equities analysts forecast that Vera Therapeutics will post -2.89 EPS for the current fiscal year.

Hedge Funds Weigh In On Vera Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of VERA. Vestal Point Capital LP lifted its stake in shares of Vera Therapeutics by 132.6% in the 1st quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company’s stock valued at $60,050,000 after purchasing an additional 1,425,000 shares during the period. Capricorn Fund Managers Ltd acquired a new position in shares of Vera Therapeutics during the third quarter valued at about $13,097,000. Price T Rowe Associates Inc. MD boosted its position in shares of Vera Therapeutics by 8.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company’s stock valued at $114,212,000 after buying an additional 377,783 shares during the last quarter. American Century Companies Inc. grew its position in Vera Therapeutics by 89.3% in the 2nd quarter. American Century Companies Inc. now owns 714,428 shares of the company’s stock worth $16,832,000 after purchasing an additional 336,978 shares in the last quarter. Finally, Hudson Bay Capital Management LP purchased a new stake in shares of Vera Therapeutics during the 2nd quarter valued at $7,044,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.